Retrospective study of various conservative treatment options with bacille Calmette-Guerin in bladder urothelial carcinoma T1G3: Maintenance therapy
| Autor: | Venancio Chantada, Martínez-Piñeiro Ja, J. Palou-Redorta, Javier C. Angulo, J.M. Fernandez, Miguel Unda, J.A. Portillo, J.L. Moyano, Rosario Madero, Eduardo Solsona |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Bladder Urothelial Carcinoma 030232 urology & nephrology Disease Bacille Calmette Guerin Conservative Treatment Bacille Calmette-Guerin Maintenance Chemotherapy Young Adult 03 medical and health sciences 0302 clinical medicine Adjuvants Immunologic Maintenance therapy Internal medicine T1G3 urothelial carcinoma Humans Medicine Neoplasm Invasiveness Transurethral resection of bladder tumour Aged Neoplasm Staging Retrospective Studies Aged 80 and over Carcinoma Transitional Cell Bladder cancer business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease Conservative treatment Urinary Bladder Neoplasms Tumor progression 030220 oncology & carcinogenesis BCG Vaccine Female Neoplasm Grading business Nonmuscle-invasive bladder tumour |
| Zdroj: | Actas Urologicas Espanolas r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Europe PubMed Central |
| ISSN: | 0210-4806 |
| Popis: | Objective: To compare various conservative treatment options for high-grade T1 nonmuscle-invasive bladder cancer (NMIBC). Bacille Calmette-Guerin (BCG) is the preferred intravesical treatment for high-grade T1 tumours; however, a number of experts still question the need for maintenance BCG. Material and methods: We retrospectively analysed data from 1039 patients with primary and recurrent T1G3 NMIBC. All patients underwent complete transurethral resection of the bladder tumour (TURBT), with muscle in the sample and multiple bladder biopsies. The patients were treated with the following: only one initial TURBT (n = 108), re-TURBT (n = 153), induction with 27 mg of BCG (Connaught strain) (n = 87), induction with 81 mg of BCG (n = 489) or induction with 81 mg of BCG + maintenance (n = 202). The time to first recurrence, progression (to T2 or greater or to metastatic disease) and specific mortality of the disease was assessed using the Kaplan-Meier survival function and were compared using the log-rank test and the Cox multivariate regression model of proportional risks. Results: The mean follow-up was 62 +/- 39 months. The risk of recurrence was significantly lower for the patients treated with maintenance therapy of 81 mg of BCG than in the other treatment groups (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|